BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2303721)

  • 1. Large scale preparation of an immunoconjugate constructed with human recombinant CD4 and deglycosylated ricin A chain.
    Ghetie V; Till MA; Ghetie MA; Uhr JW; Vitetta ES
    J Immunol Methods; 1990 Jan; 126(1):135-41. PubMed ID: 2303721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large scale preparation of immunotoxins constructed with the Fab' fragment of IgG1 murine monoclonal antibodies and chemically deglycosylated ricin A chain.
    Ghetie V; Ghetie MA; Uhr JW; Vitetta ES
    J Immunol Methods; 1988 Sep; 112(2):267-77. PubMed ID: 3262139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purification and properties of immunotoxins containing one vs. two deglycosylated ricin A chains.
    Ghetie V; Swindell E; Uhr JW; Vitetta ES
    J Immunol Methods; 1993 Nov; 166(1):117-22. PubMed ID: 8228282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin A chain using different cross-linkers.
    Ghetie V; Till MA; Ghetie MA; Tucker T; Porter J; Patzer EJ; Richardson JA; Uhr JW; Vitetta ES
    Bioconjug Chem; 1990; 1(1):24-31. PubMed ID: 2095203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond.
    Ghetie V; Thorpe P; Ghetie MA; Knowles P; Uhr JW; Vitetta ES
    J Immunol Methods; 1991 Sep; 142(2):223-30. PubMed ID: 1717600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
    Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.
    Stone MJ; Sausville EA; Fay JW; Headlee D; Collins RH; Figg WD; Stetler-Stevenson M; Jain V; Jaffe ES; Solomon D; Lush RM; Senderowicz A; Ghetie V; Schindler J; Uhr JW; Vitetta ES
    Blood; 1996 Aug; 88(4):1188-97. PubMed ID: 8695836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies.
    Vallera DA; Burns LJ; Frankel AE; Sicheneder AR; Gunther R; Gajl-Peczalska K; Pennell CA; Kersey JH
    J Immunol Methods; 1996 Oct; 197(1-2):69-83. PubMed ID: 8890895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein A vectorized toxins--I. Preparation and properties of protein A-ricin toxin conjugates.
    Ghetie MA; Laky M; Moraru I; Ghetie V
    Mol Immunol; 1986 Dec; 23(12):1373-9. PubMed ID: 3493427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covalent binding of human alpha 2-macroglobulin to deglycosylated ricin A chain and its immunotoxins.
    Ghetie MA; Uhr JW; Vitetta ES
    Cancer Res; 1991 Mar; 51(5):1482-7. PubMed ID: 1705175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
    Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
    Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
    Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
    Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice.
    Schnell R; Katouzi AA; Linnartz C; Schoen G; Drillich S; Hansmann ML; Schiefer D; Barth S; Zangemeister-Wittke U; Stahel RA; Diehl V; Engert A
    Int J Cancer; 1996 May; 66(4):526-31. PubMed ID: 8635869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function.
    Till MA; Ghetie V; May RD; Auerbach PC; Zolla-Pazner S; Gorny MK; Gregory T; Uhr JW; Vitetta ES
    J Acquir Immune Defic Syndr (1988); 1990; 3(6):609-14. PubMed ID: 2140127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.
    Schnell R; Vitetta E; Schindler J; Barth S; Winkler U; Borchmann P; Hansmann ML; Diehl V; Ghetie V; Engert A
    Leuk Lymphoma; 1998 Aug; 30(5-6):525-37. PubMed ID: 9711915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification of immunotoxins containing ricin A-chain and abrin A-chain using blue sepharose CL-6B.
    Knowles PP; Thorpe PE
    Anal Biochem; 1987 Feb; 160(2):440-3. PubMed ID: 3495199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-infected cells are killed by rCD4-ricin A chain.
    Till MA; Ghetie V; Gregory T; Patzer EJ; Porter JP; Uhr JW; Capon DJ; Vitetta ES
    Science; 1988 Nov; 242(4882):1166-8. PubMed ID: 2847316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
    Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
    Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC
    Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification of immunotoxins containing the ribosome-inactivating proteins gelonin and momordin using high performance liquid immunoaffinity chromatography compared with blue sepharose CL-6B affinity chromatography.
    Cumber AJ; Henry RV; Parnell GD; Wawrzynczak EJ
    J Immunol Methods; 1990 Dec; 135(1-2):15-24. PubMed ID: 2273254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.